Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.55 USD | +0.74% | -0.10% | +111.28% |
Financials (USD)
Sales 2024 * | 358M | Sales 2025 * | 414M | Capitalization | 2.21B |
---|---|---|---|---|---|
Net income 2024 * | 83M | Net income 2025 * | 127M | EV / Sales 2024 * | 6.19 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.34 x |
P/E ratio 2024 * |
27.1
x | P/E ratio 2025 * |
17.7
x | Employees | 624 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.47% |
Latest transcript on ADMA Biologics, Inc.
1 day | +0.74% | ||
1 week | -0.10% | ||
1 month | +46.47% | ||
3 months | +78.17% | ||
6 months | +158.11% | ||
Current year | +111.28% |
Managers | Title | Age | Since |
---|---|---|---|
Adam Grossman
CEO | Chief Executive Officer | 47 | 06-06-01 |
Compliance Officer | 37 | 10-12-31 | |
Skyler Bloom
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Guiheen
BRD | Director/Board Member | 73 | 12-07-23 |
Bryant Fong
BRD | Director/Board Member | 51 | 12-04-30 |
Steven Elms
CHM | Chairman | 60 | 06-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.03% | 1,487 M€ | +7.77% | - | |
0.01% | 9 M€ | +9.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 9.55 | +0.74% | 2,331,659 |
24-05-30 | 9.48 | +0.85% | 2,821,846 |
24-05-29 | 9.4 | -1.16% | 2,809,047 |
24-05-28 | 9.51 | -0.52% | 2,622,812 |
24-05-24 | 9.56 | +0.95% | 2,322,913 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+111.28% | 2.21B | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- ADMA Stock